Mounjaro Kwikpen 12.5mg

Like any other medicine, Mounjaro Kwikpen 12.5mg also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.
Common Side Effects Include:

• Nausea
  
• Vomiting
  
• Diarrhea
  
• Abdominal pain
  
• Indigestion
  
• Constipation

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• Dosage and duration with Mounjaro Kwikpen 12.5mg determines as per the overall health conditions of the patient.
• The usual dose of this injection is once in a week and it should be given subcutaneously in the abdomen, thigh, or upper arm.
• To get effective results take it on the same day each week and also simultaneously. Don't miss a dose or overdose the medicine.
  

Mounjaro Kwikpen 12.5mg is a prescription based medicine with active ingredient Tirzepatide. In the body it works by helping in controlling blood sugar & weight loss by copying the effects of two natural hormones such as GLP-1 (glucagon-like peptide-1) & GIP (glucose-dependent insulinotropic polypeptide).

It helps to release insulin when blood sugar is high and lowers the hormone that raises blood sugar. Additionally, it slows down the rate at which food exits your stomach, allowing you to eat less and feel fuller for longer.

Compared to other medications that simply target one hormone, this medication helps you better control your blood sugar and lose weight by working on your brain to lower appetite.

• Baker, D. E., Walley, K., & Levien, T. L. (2023). Tirzepatide. Hospital Pharmacy, 58(3), 227-243.
  
• Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., ... & Robins, D. A. (2020). Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: a 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes, Obesity and Metabolism, 22(6), 938-946.
  
• Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Landó, L. F., ... & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155.
  
• Lin, F., Yu, B., Ling, B., Lv, G., Shang, H., Zhao, X., ... & Li, Y. (2023). Weight loss efficiency and safety of tirzepatide: a systematic review. PLoS One, 18(5), e0285197.
  
• Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515.